EP067/#487 Efficacy of interstitial brachytherapy for the patient with locally advanced cervical cancer

• DOI: 10.1136/ijgc-2023-igcs.176
• Publication Date: 2023-11-08T07:00:51Z
• Authors: Tetsuya Kokabu; Koji Masui; Kohei Aoyama; Yosuke Tarumi; Hisashi Kataoka; Kaori Yoriki; Taisuke Mori
• Keywords: Chemoradiotherapy

<h3>Introduction</h3> Locally advanced cervical cancers with bulky and asymmetrical tumors treated intracavitary brachytherapy are more likely to relapse in a few years due insufficient dose prescription the entire tumor, resulting poor prognosis. The purpose of this study is evaluate efficacy safety 3-dimennsional (3D) image-guided multi-catheter interstitial brachytherapy, which could increase flexibility distribution for patients (≥4 cm) high-risk, stage IIB-IVA cancer. <h3>Methods</h3> Twenty one who underwent concurrent chemoradiotherapy between September 2014 February 2023 were enrolled. prescribed external beam radiotherapy was 45–50.4 Gy, total 25–30 Gy per 5 fractions. endpoints 5-year local pelvic control rates, disease-free overall survival adverse events rate. <h3>Results</h3> median follow-up period 53.5 months (4.1–102.0 months). Eighteen received cisplatin therapy (40 mg/m2, q1week). Five (23.9%), ten (47.6%), six (28.6%) had T2b, T3b, T4 cancer, respectively. Pelvic para-aortic lymph node metastases detected 13 (61.9%) 3 (14.3%) patients, volume before 42.6 cm³. control, progression free survival, rates 95.0%, 87.7%, 78.3%, 83.2%, Four (19.0%) experienced grade events, none 4–5 events. <h3>Conclusion/Implications</h3> 3D be promising therapeutic strategy locally